Scarica l'app Stockscreener
132.57
0.56%
-0.74
Dopo l'orario di chiusura:
131.70
-0.87
-0.66%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$133.31
Aprire:
$134.19
Volume 24 ore:
5.65M
Relative Volume:
0.93
Capitalizzazione di mercato:
$230.73B
Reddito:
$43.11B
Utile/perdita netta:
$13.94B
Rapporto P/E:
16.58
EPS:
7.9963
Flusso di cassa netto:
$6.78B
1 W Prestazione:
-1.50%
1M Prestazione:
+2.48%
6M Prestazione:
+6.48%
1 anno Prestazione:
+14.66%
Intervallo 1D:
$132.04
$134.50
Intervallo di 1 settimana:
$131.93
$135.24
Portata 52W:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Confronta ABT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
132.57 | 232.02B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.41 | 144.14B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.60 | 141.53B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.45 | 123.78B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.94 | 44.14B | 5.69B | 1.41B | 577.90M | 6.9828 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Abbott is a steady Medtech company in an unsteady world, says Benchmark - Investing.com
Abbott gets FDA breakthrough nod for dual-energy ablation catheter - MassDevice
Therapeutic Drug Monitoring (TDM) Market Size Expected to Reach USD 2.80 Bn by 2034 - GlobeNewswire Inc.
Abbott to Report Q3 Earnings: Medical Devices Arm in Focus - The Globe and Mail
Wall Street's Insights Into Key Metrics Ahead of Abbott (ABT) Q3 Earnings - Nasdaq
Abbott (ABT) Receives Buy Rating with Bullish Outlook - GuruFocus
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Abbott Laboratories: Diversified Growth and Strategic Investments Justify Buy Rating - TipRanks
Can Abbott Laboratories Deliver On Q3 Earnings Expectations? - RTTNews
Is Abbott Laboratories (ABL) stock cheap by valuation metrics2025 Earnings Surprises & Daily Entry Point Trade Alerts - newser.com
Pedialyte class action claims ‘healthy’ hydration drinks contain harmful artificial sweetener - Class Action Lawsuits
Abbott adds Laralab AI-based cardiac imaging tech - MassDevice
Abbott Laboratories: There May Be A Surge Coming Next Week (Earnings Preview) (ABT) - Seeking Alpha
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
First Merchants Corp Sells 4,988 Shares of Abbott Laboratories $ABT - MarketBeat
Maryland State Retirement & Pension System Has $11.45 Million Position in Abbott Laboratories $ABT - MarketBeat
Fluent Financial LLC Has $4.34 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Kingswood Wealth Advisors LLC Has $1.12 Million Holdings in Abbott Laboratories $ABT - MarketBeat
How Abbott Laboratories stock compares to growth peersJuly 2025 Snapshot & Stock Portfolio Risk Control - newser.com
Abbott Labs Is UBS’s Top MedTech Value Play For Growth - Finimize
Abbott Laboratories (NYSE:ABT) Given "Buy (B)" Rating at Weiss Ratings - MarketBeat
UBS reiterates Buy rating on Abbott Labs stock, citing undervalued growth - Investing.com
Puzo Michael J Trims Stake in Abbott Laboratories $ABT - MarketBeat
WoodTrust Financial Corp Acquires 8,165 Shares of Abbott Laboratories $ABT - MarketBeat
Triasima Portfolio Management inc. Buys New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT is Hendley & Co. Inc.'s 5th Largest Position - MarketBeat
Abbott Laboratories $ABT Shares Sold by NBT Bank N A NY - MarketBeat
Somerville Kurt F Has $21.58 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by BankPlus Trust Department - MarketBeat
SteelPeak Wealth LLC Increases Position in Abbott Laboratories $ABT - MarketBeat
Knights of Columbus Asset Advisors LLC Takes $329,000 Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT): A Healthcare Leader Powering the List of Profitable Dividend Stocks - MSN
Abbott Laboratories (ABT) Projected to Post Earnings on Wednesday - MarketBeat
2 Cash-Producing Stocks Worth Your Attention and 1 We Avoid - TradingView
The Bull Case For Abbott Laboratories (ABT) Could Change Following Health Canada Approval of Dissolvable Stent - simplywall.st
Vijay Kumar of Evercore ISI Group Maintains Outperform Rating fo - GuruFocus
Evercore ISI Adjusts Abbott Laboratories Price Target to $144 From $140, Maintains Outperform Rating - MarketScreener
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Abbott Laboratories' (NYSE:ABT) Returns On Capital Are Heading Higher - Yahoo
Abbott Laboratories $ABT Shares Sold by Clark & Stuart Inc - MarketBeat
The Zacks Analyst Blog Highlights Advanced Micro Devices, Abbott Laboratories and Micron Technology - Zacks Investment Research
Cullinan Associates Inc. Sells 3,000 Shares of Abbott Laboratories $ABT - MarketBeat
Joule Financial LLC Invests $675,000 in Abbott Laboratories $ABT - MarketBeat
DAVENPORT & Co LLC Buys 7,707 Shares of Abbott Laboratories $ABT - MarketBeat
Merit Financial Group LLC Purchases 6,900 Shares of Abbott Laboratories $ABT - MarketBeat
Three Bridge Wealth Advisors LLC Invests $263,000 in Abbott Laboratories $ABT - MarketBeat
Is Abbott Laboratories (ABL) stock positioned for secular growthPortfolio Update Summary & Low Drawdown Trading Strategies - newser.com
What candlestick patterns are forming on Abbott LaboratoriesMarket Risk Analysis & Risk Controlled Swing Alerts - newser.com
Simplicity Wealth LLC Purchases 14,468 Shares of Abbott Laboratories $ABT - MarketBeat
Penobscot Investment Management Company Inc. Decreases Stake in Abbott Laboratories $ABT - MarketBeat
Ameriflex Group Inc. Lowers Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):